Use of Metformin and Survival in Patients with Hepatocellular Carcinoma (HCC) Undergoing Liver Directed Therapy: Analysis of a Nationwide Cancer Registry.
Ablation
Hepatocellular carcinoma
Locoregional therapy
Metformin
Radioembolization
TACE
Journal
Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
25
08
2022
accepted:
07
05
2023
pmc-release:
01
07
2024
medline:
7
7
2023
pubmed:
23
5
2023
entrez:
22
5
2023
Statut:
ppublish
Résumé
Examine the association of metformin use and overall survival (OS) in patients with HCC undergoing image-guided liver-directed therapy (LDT): ablation, transarterial chemoembolization (TACE), or Yttrium-90 radioembolization (Y90 RE). Using National Cancer Institute Surveillance, Epidemiology, and End Results registry and Medicare claims databases between 2007 and 2016, we identified patients ≥ 66 years who underwent LDT within 30 days of HCC diagnosis. Patients with liver transplant, surgical resection, and other malignancies were excluded. Metformin use was identified by at least two prescription claims within 6 months before LDT. OS was measured by time between first LDT and death or last Medicare observation. Comparisons were performed between both all and diabetic patients on and not on metformin. Of 2746 Medicare beneficiaries with HCC undergoing LDT, 1315 (47.9%) had diabetes or diabetes-related complications. Among all and diabetic patients, 433(15.8%) and 402 (30.6%) were on metformin respectively. Median OS was greater for patients on metformin (19.6 months, 95% CI 17.1-23.0) vs those not (16.0 months, 15.0-16.9; p = 0.0238). Patients on metformin had lower risk of death undergoing ablation (HR 0.70; 0.51-0.95; p = 0.0239) and TACE (HR 0.76, 0.66-0.87; p = 0.0001), but not Y90 RE (HR1.22, 0.89-1.69; p = 0.2231). Among diabetics, OS was greater for those on metformin vs those not (HR 0.77, 0.68-0.88; p < 0.0001). Diabetic patients on metformin had longer OS undergoing TACE (HR 0.71, 0.61-0.83; p < 0.0001), but not ablation (HR 0.74, 0.52-1.04; p = 0.0886) or Y90 RE (HR 1.26, 0.87-1.85; p = 0.2217). Metformin use is associated with improved survival in HCC patients undergoing TACE and ablation.
Sections du résumé
BACKGROUND
BACKGROUND
Examine the association of metformin use and overall survival (OS) in patients with HCC undergoing image-guided liver-directed therapy (LDT): ablation, transarterial chemoembolization (TACE), or Yttrium-90 radioembolization (Y90 RE).
METHODS
METHODS
Using National Cancer Institute Surveillance, Epidemiology, and End Results registry and Medicare claims databases between 2007 and 2016, we identified patients ≥ 66 years who underwent LDT within 30 days of HCC diagnosis. Patients with liver transplant, surgical resection, and other malignancies were excluded. Metformin use was identified by at least two prescription claims within 6 months before LDT. OS was measured by time between first LDT and death or last Medicare observation. Comparisons were performed between both all and diabetic patients on and not on metformin.
RESULTS
RESULTS
Of 2746 Medicare beneficiaries with HCC undergoing LDT, 1315 (47.9%) had diabetes or diabetes-related complications. Among all and diabetic patients, 433(15.8%) and 402 (30.6%) were on metformin respectively. Median OS was greater for patients on metformin (19.6 months, 95% CI 17.1-23.0) vs those not (16.0 months, 15.0-16.9; p = 0.0238). Patients on metformin had lower risk of death undergoing ablation (HR 0.70; 0.51-0.95; p = 0.0239) and TACE (HR 0.76, 0.66-0.87; p = 0.0001), but not Y90 RE (HR1.22, 0.89-1.69; p = 0.2231). Among diabetics, OS was greater for those on metformin vs those not (HR 0.77, 0.68-0.88; p < 0.0001). Diabetic patients on metformin had longer OS undergoing TACE (HR 0.71, 0.61-0.83; p < 0.0001), but not ablation (HR 0.74, 0.52-1.04; p = 0.0886) or Y90 RE (HR 1.26, 0.87-1.85; p = 0.2217).
CONCLUSION
CONCLUSIONS
Metformin use is associated with improved survival in HCC patients undergoing TACE and ablation.
Identifiants
pubmed: 37217649
doi: 10.1007/s00270-023-03467-1
pii: 10.1007/s00270-023-03467-1
pmc: PMC10619471
mid: NIHMS1937281
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
870-879Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2023. Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
Références
Cancer Manag Res. 2019 Apr 17;11:3295-3313
pubmed: 31114366
PLoS One. 2013 Jul 29;8(7):e70010
pubmed: 23922888
Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):580-583
pubmed: 32749512
Oncol Rep. 2013 Nov;30(5):2449-57
pubmed: 24008375
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Hepatology. 2020 Mar;71(3):907-916
pubmed: 31309602
J Clin Epidemiol. 2000 Dec;53(12):1258-67
pubmed: 11146273
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Clin Res Hepatol Gastroenterol. 2022 Feb;46(2):101781
pubmed: 34332136
Hepatology. 2015 Jan;61(1):191-9
pubmed: 25142309
Int J Endocrinol. 2019 Jan 10;2019:7570146
pubmed: 30774659
Cancer Control. 2017 Jul-Sep;24(3):1073274817729244
pubmed: 28975829
Cancers (Basel). 2019 Jul 31;11(8):
pubmed: 31370248
Cardiovasc Intervent Radiol. 2021 Dec;44(12):1937-1944
pubmed: 34312687
PLoS One. 2015 Jun 01;10(6):e0127967
pubmed: 26030161
Anticancer Res. 2015 Sep;35(9):5047-54
pubmed: 26254406
Gastroenterol Res Pract. 2015;2015:570356
pubmed: 26074956
J Gastroenterol Hepatol. 2011 May;26(5):858-65
pubmed: 21251068
Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):454-64
pubmed: 26383681
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Hepatol. 2019 Apr;70(4):710-721
pubmed: 30572006
J Hepatol. 2022 Mar;76(3):681-693
pubmed: 34801630